HC Wainwright Upgrades Fate Therapeutics to 'Buy', Maintains $5.00 Price Target

Fate Therapeutics (FATE) received an upgrade to "Buy" from "Neutral" by HC Wainwright & Co. The price target remains at $5.00 USD. Recent upgrades from Wedbush and HC Wainwright & Co. indicate positivity, despite varied analyst perspectives on the company's performance. The average target price is $4.65, with an upside of 260.47% from the current price. The average brokerage recommendation is 2.3, indicating "Outperform" status. The estimated GF Value in one year is $0.49, suggesting a downside of 62.02% from the current price.